Opinion & analysis

New Year Present For Takeda As Shire Close Nears?

The wheels are turning for Takeda’s huge acquisition of Shire, assuming the European Commission’s approval on antitrust concerns, and the approval of the respective companies’ stakeholders. The $62.4b deal is the biggest overseas M&A deal in Japanese history, and brings with it speculation of future divestments by Takeda.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

New Year Present For Takeda As Shire Close Nears?

An FDA Age-Based Predicate Policy Would Be Arbitrary, Reg Experts Complain

Infographic – 2018 Pharma Pipeline Snapshot

OTC Marketing Awards 2019 Winners Announced – GSK Crowned Company Of The Year, Pfizer’s Viagra Takes Best Brand

How To Pay For The New Wave Of Gene Therapies

Data in Healthcare: Underpinning the Shift to Value

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

Father of Humira, Greg Winter, Wins 2018 Nobel Prize For Chemistry

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA’s Gottlieb Suggests

Top 10 Most Read Stories Of 2018

Herbalife Shakes Up Executive Suite Due To CEO’s Earlier Statements On Expenses

Immuno-Oncology: Unicorns, China And The Perfect Storm

US FDA’s Rush Following Novartis’ Delay Suggests Strong Displeasure With Handling Of Zolgensma Data Manipulation

Infant Formula Production Stalls On Reckitt Benckiser’s Latest Stumble

You Work In The Pharmaceutical Industry; Here’s Why You Should Care About The Novartis Payments

Going ‘Beyond The Pill’ – Sanofi To Partner With Digital Health Start-ups In Europe

Schakowsky’s Loaded Cosmetics Bill Described as ‘Floor, Not a Ceiling’ for States to Build On

What GSK’s Immunology Chief Did Next

Can Novartis Reclaim Pioneering Role In Transplantation?

Data, AI And Machine Learning Are Propelling Clinical Trials Data Analysis To New Heights

Farxiga Data Change Heart Failure Treatment Outlook

US House Panel Approves Medicare Hearing, Dental And Vision Coverage; Senate Bill Introduced

The Next New Thing In FDA Inspections: Poor Root Cause Investigations

2018’s Top Biopharma Deal-makers

‘Data Gaps’ Keep 12 Ingredients Off FDA’s Proposed OTC Sunscreen Monograph

What Does 2019 Hold For Biopharma?

Transforming Pharmaceutical R&D with Data

Let’s Make A Deal: Sanofi Regeneron Extend A Hand On Praluent, Express Scripts Takes It

Analysts Weigh Up Benefits Of Big Bayer Restructuring